Drugs / BufferGel
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00000927 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00074425 | Jan 2005 → Sep 2008 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00397670 | Jan 2004 → May 2006 | — | ReProtect Inc | Completed | No outcome recorded |
| Phase 2/3 | NCT00065858 | Sep 2001 → Apr 2005 | pregnancy disorder | Premier Research | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BufferGel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00074425 ↗ |
| Route | Topical | “Within each U.S. cohort, participants are assigned to apply BufferGel either once or twice daily.” NCT00000927 ↗ |